Among others, PD-L1, ERG, integrin-β5, survivin, TGF-β, and phosphorylated-TSC2 as well as partners of the MAP-kinase and mTOR pathways have emerged as differentially expressed endpoints in tumor-derived EVs [131]. Here, TGFB1 is linked to neoplasm.